{"id":10768,"date":"2025-09-18T09:20:14","date_gmt":"2025-09-18T08:20:14","guid":{"rendered":"https:\/\/blog.caixaresearch.org\/?p=10768"},"modified":"2025-10-28T10:54:15","modified_gmt":"2025-10-28T09:54:15","slug":"are-we-winning-the-battle-against-alzheimers","status":"publish","type":"post","link":"https:\/\/blog.caixaresearch.org\/en\/are-we-winning-the-battle-against-alzheimers\/","title":{"rendered":"Are we winning the battle against Alzheimer’s?"},"content":{"rendered":"

\"\"<\/p>\n

Science has long been able to diagnose Alzheimer’s and even predict its onset at very early stages. However, until now this was only possible by means of invasive techniques, such as lumbar punctures to examine the cerebrospinal fluid or expensive tests such as positron emission tomography (PET).<\/span><\/p>\n

Now, researchers from the <\/span>Sant Pau Research Institute (IR Sant Pau)<\/span><\/a> in Barcelona and the <\/span>BBRC<\/span><\/a> have made significant progress: they’ve demonstrated that the detection of <\/span>biomarker p-tau217<\/b> in plasma, obtained by a simple blood test, can predict not only the presence of Alzheimer’s but also its clinical progression, even before any symptoms have become evident.<\/span><\/p>\n

This finding comes at a key moment: last April the <\/span>European Medicines Agency (EMA) <\/b>authorised the sale of lecanemab (Leqembi)<\/b><\/a>, the first treatment aimed at reducing accumulation of the \u03b2-amyloid protein in the brains of people with mild cognitive impairment.\u00a0<\/span><\/p>\n

How are these advances related? And what impact will they have on patients?<\/b><\/p>\n

<